13 listed sites: United States (13) - 15 Nov `24TEV-53408 antibody treatment for nonsegmental vitiligo

TEV-53408 antibody treatment for nonsegmental vitiligo

Official title: A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo

Status: Closed to new participants

Description:

Teva Branded Pharmaceutical Products R&D LLC plans to enroll about 66 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow skin color to return. Possible risks include injection or infusion reactions, headache, and infections; longer-term risks are still being studied. People ages 18 to 75 may qualify. The study is underway but is no longer accepting new participants.

Start date: November 11, 2024

Completion date: January 31, 2029

Organizer: Teva Branded Pharmaceutical Products R&D LLC

Contact: Teva Medical Expert, MD

Link: https://clinicaltrials.gov/study/NCT06625177

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference TEV-53408 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Vitiligo and Pregnancy

    Pregnancy with vitiligo? The good news: vitiligo itself doesn’t make pregnancy unsafe. Most women stay stable (some even improve), though flares can pop up after birth — usually...

  • What is the best therapy for localized vitiligo?

    Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...

  • Vitiligo trials for kids: basics for the parents

    Pediatric vitiligo trials · The basics Two parallel studies are evaluating investigational use of ruxolitinib cream in young children — researchers are still finding out how wel...